TCT-188 Two-Year Clinical Outcome of Patients With Bifurcation Lesions Treated With Second-generation Zotarolimus-Eluting Resolute Stents and Everolimus-Eluting Xience V Stents in the Randomized TWENTE Trial

Kenneth Tandjung, Hanim Sen, Ming Kai Lam, Marije M. Löwik, Gert van Houwelingen, Martin G. Stoel, Hans W. Louwerenburg, Frits de Man, Gerard C.M. Linssen, Rogier Nijhuis, Mark B. Nienhuis, Clemens von Birgelen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: The aim of this study was to investigate safety and efficacy of second-generation zotarolimus-eluting Resolute stents and everolimus-eluting Xience V stents in bifurcation lesions.

Methods: In TWENTE - a prospective, randomized DES trial - PCI patients were randomized for treatment with contemporary Resolute or Xience V stents. Clinical endpoints were adjudicated by an external independent clinical events committee (Cardialysis CRO, Rotterdam, The Netherlands). Target vessel failure (TVF; cardiac death, target vessel-related myocardial infarction, and clinically-indicated target vessel revascularization), the primary endpoint of the TWENTE trial, was assessed after 2 years.

Results: Among the 1,391 patients of the TWENTE trial, 362 (26%) patients were treated for at least one bifurcation lesion. Of these patients, 179 and 183 were randomized for treatment with Resolute and Xience V stents, respectively. At 2-year follow-up, TVF (12.8% vs. 11.5%; p=0.69) and a patient-oriented composite endpoint (17.3% vs. 16.9%; p=0.92) did not differ significantly between stent arms. In addition, rates of definite and or probable stent thrombosis were low and similar for both stent arms (0.6% vs. 0.5%; p=0.99). Within 213 (15.3%) patients, who were treated for bifurcation lesions with an additional treatment of the side-branch, there was also no significant difference in TVF between patients treated with Resolute (n=98) and Xience V (n=115) (8.2% vs. 11.3%; p=0.44).

Conclusions: Treatment of bifurcation lesions with Resolute and Xience V stents resulted in favorable and similar outcomes after 2 years in the randomized TWENTE trial.
Original languageEnglish
Pages (from-to)B61-B61
JournalJournal of the American College of Cardiology
Volume62
Issue number18, Suppl. 1
DOIs
Publication statusPublished - 2013
Event25th Annual Scientific Symposium of Transcatheter Cardiovascular Therapeutics, TCT 2013 - San Francisco, United States
Duration: 27 Oct 20131 Nov 2013
Conference number: 25

Keywords

  • IR-89484
  • METIS-302489

Fingerprint Dive into the research topics of 'TCT-188 Two-Year Clinical Outcome of Patients With Bifurcation Lesions Treated With Second-generation Zotarolimus-Eluting Resolute Stents and Everolimus-Eluting Xience V Stents in the Randomized TWENTE Trial'. Together they form a unique fingerprint.

  • Cite this